财经
Look for M&A activity in biotech, says Kevin Mahn
Hennion & Walsh's CIO tells Reuters' Fred Katayama biotech firms with drugs already in the pipeline are prime acquisition targets for big drug makers.
财经
for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up